European Commission approves Roche's Vabysmo for treating macular edema due to retinal vein occlusion.
The European Commission approves Roche's Vabysmo for treating visual impairment due to macular edema secondary to retinal vein occlusion (RVO). The drug, also approved for nAMD and DME, has demonstrated early and sustained vision improvements in Phase III studies, BALATON and COMINO, and provides robust retinal drying. Vabysmo has been approved in over 90 countries and is expected to be a new treatment option for RVO patients in Europe.
July 30, 2024
4 Articles